The trial's data show that patients who were less likely to have Alzheimer's co-pathology demonstrated progressively improved treatment responses. Dr. John-Paul Taylor, the chief investigator of the trial, emphasized the importance of using plasma pTau181 levels to identify patients who are most likely to benefit from neflamapimod. The findings suggest that neflamapimod could effectively slow disease progression in patients with 'pure' DLB, as it targets the neuroinflammation and synaptic dysfunction associated with the condition.
Dr. John Alam, CEO of CervoMed, expressed optimism about the upcoming Phase 3 trial, stating that the data supports their patient enrichment strategy and dosing regimen. The company plans to initiate this pivotal trial in the second half of 2026, pending funding. The trial's results are expected to enhance the understanding of neflamapimod's efficacy and its potential to improve cognitive and functional outcomes for patients suffering from DLB.
CervoMed's commitment to addressing the unmet medical needs in DLB is underscored by the positive results from the RewinD-LB trial, which was funded primarily by a $21.3 million grant from the National Institutes of Health. As the company moves forward, it aims to leverage these findings to secure additional funding and support for its clinical development efforts.
